Cell and Gene Therapy Size Is Projected to Reach US$ 35.4 Billion at a CAGR of 21.9% Till 2027 | Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer

Biological products include a wide range of products such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Many biologics are produced using recombinant DNA technology. Biologics are the best used drugs for genetic disorders. New technologies, novel therapies are emerging for manufacturing of new biologics, which hold a prominent future for the global biologics market. Biologics are widely used to prevent, treat, diagnose, or cure a variety of diseases including cancer, chronic kidney disease, autoimmune disorders, and infectious diseases. Biologics are also used to treat children with CLN2 disease, which is a form of Batten disease. In 2017, BioMarin Pharmaceutical Inc. received the U.S. FDA approval for its Brineura (cerliponase alfa), which is indicated for the treatment CLN2 disease.

Get Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2663

Global Biologics Market: Drivers

The global biologics market size is expected to increasing, owing to increasing product pipeline from different companies such as Merck and Co., Pfizer, and GlaxoSmithKline. Pfizer has a strong product pipeline for 2019 of biologics, biosimilars, vaccines, and small molecules. Its 35 products are in phase 1, 28 are in phase 2, 26 are in phase 3, and 11 products are in the process of registration. In 2018, the U.S. FDA approved Pfizer’s DAURISMO (glasdegib) in the U.S. for adult patients with newly-diagnosed acute myeloid leukemia for whom intensive chemotherapy is not an option.

Furthermore, the global biologics market revenue is growing due to of increasing regulatory approvals for new biologic medicines for treatment of rare diseases. For instance, in 2017, the U.S. FDA approved 46 biologics and in December 2017, GlaxoSmithKline’s biologic Nucala was approved for the treatment of a rare disease called eosinophilic granulomatosis, with polyangiitis (EPGA).

Global Biologics Market Regional Analysis

North America holds dominant position in the global biologics market, owing to presence of major pharmaceutical and biopharmaceutical companies in the U.S. such as AbbVie, Amgen, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck and Co., Novartis, Pfizer, and Sanofi. In 2018, 59 novel drugs and biologics were approved in by the U.S. FDA’s Center for Drug Evaluation and Research and were launched in the U.S.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/biologics-market-3010

Asia Pacific is expected to witness significant growth in the global biologics market, owing to increasing production and manufacturing of biosimilar products of biologics. A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company. For instance, Indian biopharmaceutical company Biocon Ltd., launched two biosimilars CANMAb (trastuzumab) and Krabeva (bevacizumab) in India in year 2014 and 2017 respectively for treatment of several types of cancer.

Global Biologics Market: Competitive Landscape

Key players operating in the global biologics market include AbbVie, Amgen, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck and Co., Merck KGaA, Novartis, Pfizer, F. Hoffmann-La Roche Ltd, and Sanofi.

Buy Now this Premium Report 2021: https://www.coherentmarketinsights.com/insight/buy-now/2663

Global Biologics Market: Taxonomy

The global biologics market is segmented on the basis of product type, application, end user, and region.

By Product Type
• Monoclonal Antibodies
• Vaccines
• Recombinant Hormones/Proteins
• Cell Therapy
• Gene Therapy

By Application
• Oncology
• Infectious Diseases
• Immunology
• Autoimmune Diseases
• Others

Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.